Bradford J. Sandler, Esq. (NY Bar No. 4499877) Ilan D. Scharf, Esq. (NY Bar No. 4042107) Jason S. Pomerantz, Esq. (Admitted *pro hac vice*) PACHULSKI STANG ZIEHL & JONES LLP 780 Third Avenue, 34th Floor New York, New York 10017

Telephone: (212) 561-7700 Facsimile: (212) 561-7777

Counsel to Plaintiff RDC Liquidating Trust

UNITED STATES BANKRUPTCY COURT WESTERN DISTRICT OF NEW YORK

In re:

ROCHESTER DRUG CO-OPERATIVE, INC.

Debtor.

Advisory Trust Group, LLC, as trustee of the RDC LIQUIDATING TRUST,

Plaintiff,

v.

NEPHRON PHARMACEUTICALS CORPORATION,

Defendant.

Chapter 11

Case No. 20-20230 (PRW)

Adv. Proc. No. 22-02069 (PRW)

CERTIFICATION AND REPORT OF RULE 26(f) FRCP/RULE 7026 FRBP CONFERENCE AND DISCOVERY PLAN

Advisory Trust Group, LLC, in its capacity as the Liquidating Trustee of the RDC Liquidating Trust ("**Plaintiff**") and Nephron Pharmaceuticals Corporation ("**Defendant**") submit the following report and discovery plan in accordance with the Rule 7026 of the Federal Rules of Bankruptcy Procedure ("**FRBP**"), incorporating Rule 26 of the Federal Rules of Civil Procedure ("**FRCP**"), and the Court's guidelines.

1. <u>Certification Concerning Discovery Plan.</u>

A discovery plan is needed or useful in this case and is outlined below.

- 2. <u>Certification of Conference</u>. Pursuant to Rule 26(f) FRCP/Rule 7026 FRBP, a meeting was held on April 28, 2022 by telephone and was conducted by the undersigned counsel for the designated parties in this adversary proceeding.
- 3. **Pre-Discovery Disclosures**. The information required by Rule 26(a)(1) FRCP and Rule 7026 FRBP will be exchanged by May 12, 2022.
- 4. **<u>Discovery Plan</u>**. The parties jointly propose to the Court the following discovery plan:
 - a. All non-expert discovery will be completed by August 31, 2022.
 - b. All expert witness disclosures required by Rule 26(a)(2) will be exchanged by September 9, 2022. Any expert report intended solely to contradict or rebut evidence on the same subject matter identified by anther party under Rule 26(a)(2)(B) or (C) must be disclosed by October 31, 2022. All expert witness discovery will be completed by December 30, 2022.
 - c. Discovery limits:
 - i. Non-expert discovery: maximum of 3 depositions by each party.
 - ii. Expert discovery: shall be conducted as necessary. At this time, the parties anticipate no more than one expert each.
- 5. <u>**Dispositive Motions**</u>. All potentially dispositive motions should be filed by August 31, 2022, and not before completion of the Rule 16 Conference.

6.	Settlement:

[] is likely.	
[] is unlikely.	
[] cannot be evaluated prior to	(date).
[] the parties consent to the Court's active particip	eation in settlement discussions.
[X] the parties continue to discuss settlement, and it matter will settle.	t is unclear at this time whether the

[Remainder of Page Intentionally Left Blank]

- 7. **Trial**. The case should be ready for trial by February 1, 2023 and should take 1-2 days.
- 8. All parties consent to this Court entering final judgment.

PACHULSKI STANG ZIEHL & JONES LLP Date: May 2, 2022

/s/ Jason S. Pomerantz

Ilan D. Scharf (NY Bar No. 4042107) Jason S. Pomerantz (CA Bar No. 157216)

780 Third Avenue, 34th Floor

New York, NY 10017

Telephone: (212) 561-7700 Email: ischarf@pszjlaw.com

jspomerantz@pszjlaw.com

Counsel to Plaintiff RDC Liquidating Trust

Date: May 2, 2022 NEXSEN PRUET, LLC

/s/ Carl H. Petkoff

Julio E. Mendoza, Jr. (Admitted Pro Hac Vice) Carl H. Petkoff (Admitted Pro Hac Vice)

1230 Main Street, Suite 700

Columbia, SC 29201

Telephone: (803) 540-2189

Email: RMendoza@nexsenpruet.com CPetkoff@nexsenpruet.com

Counsel to Defendant Nephron Pharmaceuticals Corporation